logo

For the Inventor, By the Inventor

Como, Italy

Giovanni Cervi

USPTO Granted Patents = 9 


 

Average Co-Inventor Count = 6.4

ph-index = 3

Forward Citations = 55(Granted Patents)


Company Filing History:

goldMedal9 out of 138 
 
Nerviano Medical Sciences S.r.l.
 patents

Years Active: 2012-2016

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 9284298 - Pyrazolyl-pyrimidine derivatives as kinase inhibitors (2016-03-15),
2. 8993594 - Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors (2015-03-31),
3. 8981092 - Substituted 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-ones as modulators of protein kinase activity (2015-03-17),
4. 8946250 - 3,4-diarylpyrazoles as protein kinase inhibitors (2015-02-03),
5. 8592416 - Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors (2013-11-26),
6. 8541575 - 3,4-diarylpyrazoles as protein kinase inhibitors (2013-09-24),
7. 8513241 - 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them (2013-08-20),
8. 8394802 - 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases (2013-03-12),
9. 8207165 - 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them (2012-06-26),

Title: Giovanni Cervi: Innovator in Pharmaceutical Chemistry

Introduction

Giovanni Cervi is a prominent inventor based in Como, Italy, known for his significant contributions to pharmaceutical chemistry. With a total of nine patents to his name, he has made remarkable advancements in the field of kinase inhibitors and PARP-1 inhibitors.

Latest Patents

Cervi's latest patents include the development of pyrazolyl-pyrimidine derivatives as kinase inhibitors. This invention relates to compounds that modulate the activity of protein kinases, which are crucial in treating diseases caused by dysregulated protein kinase activity. The invention also encompasses methods for preparing these compounds, pharmaceutical compositions containing them, and methods of treating diseases utilizing these compounds.

Another notable patent is for isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors. These substituted derivatives selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1, making them useful in treating various diseases, including cancer, cardiovascular diseases, central nervous system injuries, and different forms of inflammation. This patent also provides methods for preparing these compounds and pharmaceutical compositions that include them.

Career Highlights

Giovanni Cervi is currently associated with Nerviano Medical Sciences S.r.l., where he continues to innovate and contribute to the field of pharmaceutical research. His work has been instrumental in developing new therapeutic options for various diseases.

Collaborations

Cervi collaborates with several talented individuals in his field, including Gianluca Mariano, Enrico Papeo, and Fabio Zuccotto. These collaborations enhance the research and development efforts at Nerviano Medical Sciences S.r.l.

Conclusion

Giovanni Cervi's innovative work in pharmaceutical chemistry, particularly in the development of kinase and PARP-1 inhibitors, showcases his dedication to advancing medical science. His contributions are paving the way for new treatments that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…